Anti-Human GPC3 Therapeutic Single Domain Antibody (HN3) (CAT#: TAB-416CQ)

This antibody binds to a unique conformational epitope in the native form of GPC3 core protein on cancer cells with high affinity. The binding requires both the N-terminus and C-terminus domains of GPC3, and is independent of the HS chains on GPC3.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Published Data
  • Datasheet
  • MSDS
  • COA
ELISA

Figure 1 Binding properties of HN3 antibody.

Protein-binding affinity was measured by ELISA using purified GPC3-hFc. (D) Measurement of cell-binding affinity by FACS using the G1 cell line.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.

Figure 2 Binding properties of HN3 antibody.

Measurement of cell-binding affinity by FACS using the G1 cell line.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.

IP

Figure 3 Binding properties of HN3 antibody.

Immunoprecipitation assay using coexpressed GPC3 N- and C-terminal fragments.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.

IHC

Figure 4 Binding properties of HN3 antibody.

HCC tissue immunohistochemistry staining with HN3.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.

FuncS

Figure 5 The effect of yap deregulation on HN3 function.

HN3 treatment of yap-knockdown cells. Proliferation was normalized with unengineered cells without antibody treatment.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.

FuncS

Figure 6 The effect of yap deregulation on HN3 function.

HN3 treatment of cells overexpressing yap-S127A.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.

WB

Figure 7 The effect of yap deregulation on HN3 function.

Western blot analysis of molecular changes after HN3 treatment on yap-knockdown cells or cells overexpressing yap-S127A.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.

ELISA

Figure 8 Inhibition of HCC xenograft tumor growth by HN3 antibody.

Pharmacokinetics of HN3 antibody. Serum concentrations of the antibody were measured by ELISA following a single i.v. injection of 3 mg/kg. The serum antibody concentration data were fitted with a two-compartment model using Phoenix WinNonlin software. The observed mean serum antibody concentration (in micrograms per milliliter) ± SD of four animals for each time point was plotted as a function of time.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.

Inhib

Figure 9 Inhibition of HCC xenograft tumor growth by HN3 antibody.

Inhibition of HepG2 cells inoculated into nude mice. After the tumor size reached 100 mm³, HN3 antibody or hIgG control was delivered i.v. at 60 mg/kg body weight, twice a week. Arrows indicate antibody injections.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.

Inhib

Figure 10 Inhibition of HCC xenograft tumor growth by HN3 antibody.

Inhibition of Huh-7 cells inoculated into nude mice. After the tumor size reached 100 mm³, HN3 antibody or hIgG control was delivered i.v. at 60 mg/kg body weight, twice a week. Arrows indicate antibody injections.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.

WB

Figure 11 Inhibition of HCC xenograft tumor growth by HN3 antibody.

Western blot analysis of molecular changes in HN3-treated and control tumors.

Feng, M., Gao, W., Wang, R., Chen, W., Man, Y. G., Figg, W. D., ... & Ho, M. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 110(12), E1083-E1091.


Specifications

  • Host Species
  • Human
  • Derivation
  • Phage display library
  • Type
  • Single domain antibody
  • Specificity
  • Human
  • Species Reactivity
  • Human
  • Clone
  • HN3
  • Applications
  • Immunoprecipitation, Immunohistochemistry, Functional Assay, Western Blot, ELISA, Inhibition
  • Related Disease
  • Hepatocellular carcinoma

Applications

  • Application Notes
  • The antibody was validated for Immunoprecipitation, Immunohistochemistry, Functional Assay, Western Blot, ELISA, Inhibition. For details, refer to Published Data.

Target

  • Alternative Names
  • GPC3; glypican 3; SGB; DGSX; MXR7; SDYS; SGBS; OCI-5; SGBS1; GTR2-2; glypican-3; secreted glypican-3; glypican proteoglycan 3; intestinal protein OCI-5; heparan sulphate proteoglycan

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

See other products for "GPC3"


For Research Use Only. Not For Clinical Use.

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

© 2021 Creative BioLabs. All Rights Reserved
  • 0
  • 0

Cart